Collagen and Cellulite

What the trials measured

The most direct evidence comes from a 6-month, double-blind, placebo-controlled randomized trial in 105 women aged 24 to 50 with moderate cellulite. Participants took about 2.5 g/day of oral collagen peptides or placebo, and investigators assessed the degree of cellulite along with skin waviness, dermal density, and the length of the subcutaneous borderline. Collagen peptide intake was associated with a statistically significant decrease in the degree of cellulite compared with placebo, and the effect was more pronounced in normal-weight women than in overweight women.^{[1], [2]}

A systematic review of oral collagen supplementation in dermatology pooled 11 randomized placebo-controlled trials in 805 patients. Several of those trials used collagen hydrolysate at roughly 2.5 to 10 g/day for indications that included cellulite and skin aging, and the review noted improvements in measures such as skin elasticity, hydration, and dermal collagen density. This review provides supporting context for the dose range and the kinds of skin outcomes that have been measured.^{[1], [2]}

Tolerability in the studies

Across the randomized dermatology trials summarized in the systematic review, oral collagen supplements taken at about 2.5 to 10 g/day were described as generally well tolerated, with no adverse events reported. Absence of reported adverse events in short trials is not a formal safety assessment, and data on longer-term use and on specific populations remain limited.^[2]

How strong is the evidence

The human evidence connecting oral collagen peptides to cellulite improvement is limited. The strongest single study is one small RCT, and the supporting systematic review explicitly described the overall results for oral collagen in dermatology as preliminary while calling for further studies to determine optimal dosing. Larger, independent, and longer trials focused specifically on cellulite would be needed before drawing firmer conclusions.^{[1], [2]}

Limitations of the evidence

Findings on cellulite rest largely on a single small randomized trial of 105 women plus a systematic review whose authors characterized the broader oral-collagen literature as preliminary. The trial population was limited to women aged 24 to 50, the effect was smaller in overweight participants, and follow-up was 6 months or less. Optimal dosing, durability of any benefit, and effects in other populations remain undetermined.^{[1], [2]}

Reported tolerability is reassuring but comes from short trials in generally healthy adults, so the absence of reported adverse events should not be read as a guarantee of safety across all people or longer-term use.^[2]